Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Acquired byShire
Price$565M
Date8/2010

General Information

Websitemovetis.com
CategoryBioTech
Phone32 1 440 43 90
Employees
Founded2006
DescriptionPharmaceutical Developer

Offices

Turnhout, BEL
Veedijk 58 1004
Turnhout, 2300, BEL

People

CEO and Co-founder
Board of Directors

Funding

TOTAL $191M
FUNDING TOTAL $191M
Series A, 1/2007
Sofinnova Partners
Life Sciences Partners
Sofinnova Ventures
KBC
Gimv
Quest for Growth
BIP Investment Partners
€49M
Private Equity, 12/2009
Credit Suisse
$128M

Tags

Movetis

Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company’s lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is also tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patient’s refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.

Recent Milestones

Videos

Screenshots

Movetis screenshot
Above: Home Page
Uploaded: 12/4/09

Sources

  1. Shire forges $565M buyout deal for Movetis (fiercebiotech.com) [edit]
  2. MOVETIS NV Closes 49 Million EUR Series A Financing Round (bip.lu) [edit]
  3. Belgian Pharma Co. Movetis Raises $127.5M In IPO (fis.dowjones.com) [edit]
Edit This Page
Last Edited 3/29/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy